Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

Velasco, Roser; Bruna, Jordi; Briani, Chiara; Cavaletti, Guido; Alberti, Paola; Frigeni, Barbara; Cacciavillani, Mario; Cortinovis, Diego; Cazzaniga, M.; Santos, Cristina

doi:10.1136/jnnp-2013-305334

Cited by 126 publications

(122 citation statements)

References 38 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Studies show that the neurotoxic side effects are greatly affected by cumulative doses and are predominantly found in men [14] [16] [18]. These side effects may be permanent and should be weighed against the increased chance of survival that oxaliplatin gives [3] [15] [32].…”

Section: Discussionmentioning

confidence: 99%

“…Permanent damage may occur without acute side effects in the initial stage [13]. Studies show that the neurotoxic side effects greatly affect the duration of chemotherapy; therefore, deciding whether the dosage of oxaliplatin should be reduced or treatment stopped for fear of debilitating and prolonged neurotoxicity is an important issue [14]- [18]. Although a number of interventions for chemotherapy-induced neurotoxicity have been tested, none of them can be recommended for clinical use due to lack of evidence [19]- [21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

Drott¹,

Starkhammar²,

Börjeson³

et al. 2014

OJN

View full text Add to dashboard Cite

Patients with colorectal cancer (CRC) can have chemotherapy with oxaliplatin postoperatively. Oxaliplatin can cause acute and chronic neurotoxicity. It is important to be aware of neurotoxic side effects so they can be documented and action taken at an early stage. The study aimed to identify and explore neurotoxic side effects documented in the medical records of patients with colorectal cancer treated with oxaliplatin-based adjuvant chemotherapy. Data in this study were medical records; presenting documentation about patients treated at the University Hospital in the south of Sweden between 2009 and 2010. A summative content analysis approach was used to explore the neurotoxic side effects. Identification and quantification of the content of medical records were carried out by using a study-specific protocol. "Cold sensitivity" and "tingling in the hands" were the most frequently documented neurotoxicity-related terms in the medical records. This identification was followed by interpretation. Three categories were identified in the interpretive part of the study: acute, chronic, and degree of neurotoxicity. The results show the importance of awareness of neurotoxic side effects so that they can be documented and action taken at an early stage. The documentation could be more reliable if patient-reported structured measurements were used, combined with free descriptions in the medical records. Being able to follow the progression of the symptoms during and after treatment would improve patient's safety and also quality of life. The protocol that we developed and used in this review of medical records may be helpful to structure the documentation in the electronic system for documentation of neurotoxicity side effects. Keywords

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

Drott¹,

Starkhammar²,

Börjeson³

et al. 2014

OJN

View full text Add to dashboard Cite

show abstract

“…This would potentially abate the need to terminate chemotherapy treatment by permitting early identification of patients at risk of high-grade neuropathy allowing prompt chemotherapy dose reduction before nerve damage occurs. 78 Work is currently ongoing to identify and investigate novel biomarkers for CIPN.…”

Section: Detection/diagnosismentioning

confidence: 99%

Pain in cancer survivors

Brown

Ramirez

Farquhar-Smith

2014

British Journal of Pain

View full text Add to dashboard Cite

Cancer and its treatment exert a heavy psychological and physical toll. Of the myriad symptoms which result, pain is common, encountered in between 30% and 60% of cancer survivors. Pain in cancer survivors is a major and growing problem, impeding the recovery and rehabilitation of patients who have beaten cancer and negatively impacting on cancer patients' quality of life, work prospects and mental health. Persistent pain in cancer survivors remains challenging to treat successfully. Pain can arise both due to the underlying disease and the various treatments the patient has been subjected to. Chemotherapy causes painful chemotherapy-induced peripheral neuropathy (CIPN), radiotherapy can produce late effect radiation toxicity and surgery may lead to the development of persistent post-surgical pain syndromes. This review explores a selection of the common causes of persistent pain in cancer survivors, detailing our current understanding of the pathophysiology and outlining both the clinical manifestations of individual pain states and the treatment options available.

show abstract

“…Oxaliplatin is one of these drugs and it is frequently used today, usually combined with 5-fluorouracil (5-FU) and folinic acid (leucovorin) (1)(2). Survival among patients with CRC has been shown to improve when oxaliplatin is added to the treatment, even when the patient is in later stages of the disease when diagnosed (3).…”

Section: Introductionmentioning

confidence: 99%

“…It is also known, in comparison with other combinations, that patients receiving a combination that includes oxaliplatin have their symptoms for a longer time than patients receiving other combinations (5). Oxaliplatin has recently been introduced in the treatment of other forms of cancer in the gastro-intestinal tract (GI-tract), such as oesophagus-, gastric-and pancreatic cancer (2,(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

Gustafsson

Litström

Berterö

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

Cited by 126 publications

References 38 publications

Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

Pain in cancer survivors

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

Contact Info

Product

Resources

About